ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that its branded marketing subsidiary, ECR Pharmaceuticals will promote Urocit^®-K 15mEq, potassium citrate extended release tablets to primary care physicians beginning in April, 2010. Hi-Tech has a license agreement with Mission Pharmacal Company, which will promote the product to Urologists. Indicated for the treatment of kidney stones, UroCit^®-K 15mEq is the maximum strength potassium citrate product available, and provides convenient twice-a-day dosing Urocit-K 15 mEq offers kidney stone sufferers the only twice-daily treatment at this dosage strength. The new formulation provides patients with 50 percent more of the active ingredient, potassium citrate, than Urocit-K 10 mEq. ECR Pharmaceuticals will receive a percentage of gross profit based on prescriptions generated by primary care physicians.

“UroCit®-K 15mEq is a highly effective product, available in a convenient dosing regimen which will increase patient compliance.”

"We are pleased to introduce another unique prescription branded product to the primary care market," said David Seltzer, President and CEO of Hi-Tech Pharmacal. "UroCit^®-K 15mEq is a highly effective product, available in a convenient dosing regimen which will increase patient compliance."

Terry Herring, president of Mission Pharmacal’s Pharmaceutical Division stated that, “We are pleased with our new arrangement with ECR. At Mission, our goal is to bring innovative products to Physicians and their patients. This partnership demonstrates our commitment to delivering on that goal. Through this effort more patients will receive better care. Mission Pharmacal continues to invest in research and development to improve treatment outcomes of nephrolithiasis (kidney stones) for physicians and patients.”